What Protean BioDiganostics Inc does

Protean BioDiagnostics Inc is a privately held precision oncology diagnostics company founded by Dr. Anthony M. Magliocco and headquartered in Orlando, Florida, where it operates a CAP/CLIA-certified high-complexity clinical laboratory. The company delivers advanced cancer diagnostic testing, hereditary cancer risk assessment, and treatment-decision support primarily to community-based oncologists, hospital and health-system laboratories, cancer patients, and pharmaceutical/CRO partners. Its proprietary platform, Protean MAPS (Multi-Omic Analysis and Precision Medicine System), integrates multiple diagnostic modalities — tissue testing, liquid biopsy, genetic testing, methylation/epigenetic analysis, and digital pathology imaging — with telemedicine-backed decision support and AI clinical trial matching, and is positioned as the only comprehensive precision medicine system explicitly designed for community-based cancer patients.

The technology stack is largely assembled through strategic partnerships and licensing rather than wholly internal development. Core offerings include Risk MAPS (whole exome sequencing-based hereditary risk assessment), Aventa FusionPlus (a 3D genomics clinical test for gene fusions across 361 genes, developed via the Aventa Genomics joint venture with Arima Genomics), CDX Prostate (AI-powered prostate cancer risk scoring via Nanostics' ClarityDX platform), HDPCR NSCLC Assay (ChromaCode multiplexing), Travera Rapid Therapy Guidance (functional profiling of live tumor cells against FDA-approved therapies), and the Pictor ENA IgG Multiplex ELISA for autoimmune disease. Additional capabilities include variant annotation pipelines interoperating with Roche NAVIFY, SOPHiA DDM, QIAGEN Clinical Insight Interpret, and Genoox, as well as a CLIA Digital Pathology Imaging Laboratory using computer-vision-based image analysis.

The company generates revenue primarily on a fee-for-service laboratory testing basis, billing physicians, hospitals, insurance, and patients per test with quote-based pricing that is not publicly disclosed. A secondary revenue stream comes from contract research organization (CRO) services covering CLIA development, clinical trial support, and companion diagnostics development for pharmaceutical and biotechnology clients. Protean employs 51-100 staff, holds state laboratory licensure in Florida, California, and New York, and has operated with minimal disclosed external capital — a single disclosed funding round of $330,000 in 2019 — supplemented by non-dilutive support from the Florida SBDC at UCF and the UCF Business Incubation Program at Lake Nona.

Name

Protean BioDiganostics Inc

Legal name

Protean BioDiagnostics Inc

Website

https://proteanbiodx.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

Protean BioDiagnostics is a CAP/CLIA-certified precision oncology laboratory in Orlando, Florida, operating the proprietary Protean MAPS platform that integrates multi-omic cancer profiling, AI-powered clinical trial matching, telemedicine decision support, and hereditary risk assessment for community oncologists, hospitals, and patients.

Ownership category

akta.pro rank

Product category

Precision Oncology Clinical Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)

akta.pro secondary industries

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Precision oncology diagnostics
• Cancer profiling services
• Clinical laboratory testing
• Hereditary cancer screening
• Companion diagnostics development

Headquarters

HQ city

Orlando

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Clinical Laboratory Testing Services: Protean operates a CAP/CLIA-accredited, high-complexity laboratory performing cancer diagnostic tests for physicians, hospitals, and patients. Revenue is generated through fee-for-service laboratory testing billed to healthcare providers, insurance, and patients.
2. Genetic Risk Assessment Testing: Risk MAPS™ hereditary cancer testing services using cheek swab samples with whole exome sequencing analysis, billed as laboratory services.
3. Research Services: CRO services including CLIA development, clinical trials support, and companion diagnostics development for pharmaceutical and biotechnology partners.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Protean BioDiagnostics operates a CAP/CLIA-certified clinical laboratory in Orlando, Florida, that delivers precision oncology diagnostic testing and cancer profiling through its proprietary Protean MAPS platform. The company sells cancer screening, hereditary genetic testing (Risk MAPS), AI-powered prostate cancer risk assessment (CDX Prostate), 3D genomics gene fusion testing (Aventa FusionPlus), lung cancer diagnostics (HDPCR NSCLC Assay), functional therapy guidance (Travera), autoimmune diagnostics (Pictor ENA), and telemedicine-backed oncology consultations. It also provides CRO services including CLIA development, clinical trial support, and companion diagnostics development for pharmaceutical and biotechnology partners.

Product overview

Protean BioDiagnostics offers Protean MAPS as the core comprehensive cancer profiling platform that integrates health screening, diagnostics, treatment guidance, and telemedicine-backed decision support. The platform encompasses multiple specialized products: Risk MAPS for hereditary cancer risk assessment via whole exome sequencing; CDX Prostate (via Nanostics partnership) for AI-powered prostate cancer risk scoring; Aventa FusionPlus (joint venture with Arima Genomics) as the first 3D genomics test for solid tumors; HDPCR NSCLC Assay (with ChromaCode) for rapid lung cancer diagnostics; Travera Rapid Therapy Guidance for treatment response profiling; and Pictor ENA IgG Multiplex ELISA for autoimmune diagnostics. Services include cancer consultations, CRO services, research services, methylation/epigenetics testing, CLIA development, and clinical trials support. All services are delivered through their CAP/CLIA-certified laboratory in Orlando, Florida.

Differentiator

Problem solved

Functional benefit

Brands

• Protean MAPS: Proprietary comprehensive cancer profiling system integrating screening, diagnostics, treatment guidance, and telemedicine decision support for community-based cancer patients.
• Risk MAPS

Products and services

• Protean MAPS Proprietary cancer profiling system that incorporates the highest quality tests available and delivers rapid results with decision support and precision oncology guidance for all cancer types; includes telemedicine, virtual tumor boards, and AI clinical trial matching for oncologists and patients.
• Risk MAPS Hereditary Cancer Testing Whole exome sequencing-based hereditary cancer risk assessment offering unprecedented coverage of the human genome for cancer prevention and treatment planning; cheek swab sample collection enables at-home or in-office testing for patients and at-risk individuals.
• CDX Prostate (ClarityDX Prostate) Blood-based AI-powered diagnostic test for men at risk of aggressive prostate cancer, used as a reflex test following elevated PSA or abnormal DRE; uses biological data, clinical information, and machine learning models to generate risk scores. Performed in Protean's CLIA-certified Orlando laboratory.
• Aventa FusionPlus First 3D genomics clinical test detecting gene fusions, translocations, and rearrangements across 361 genes from FFPE tumor tissue using spatial proximity preservation for 100-1000x signal amplification; developed via the Aventa Genomics joint venture between Arima Genomics and Protean.
• HDPCR NSCLC Assay Non-small cell lung cancer assay based on ChromaCode's High Definition PCR (HDPCR) multiplexing technology delivering rapid turnaround and clinically relevant markers for lung cancer diagnostics; addresses cost, turnaround, and tissue sample barriers in NSCLC.
• Travera Rapid Therapy Guidance Functional profiling test that uses tissue or fluid to screen live tumor cells against approved anti-cancer therapies; indicated for 39 different cancers and 100+ FDA-approved therapies to guide treatment selection for advanced carcinoma patients.
• Pictor PictHealth ENA IgG Multiplex ELISA Next-generation multiplexed ELISA test for autoimmune disease diagnosis identifying antibodies associated with lupus and connective tissue disorders, developed in partnership with Pictor, Inc.
• Cancer Screening Tests Comprehensive cancer screening services for early detection across multiple cancer types offered through Protean's CAP/CLIA-certified laboratory; supports physicians and patients with early cancer detection.
• Cancer Consultations Expert oncology consultations for cancer patients including diagnosis confirmation, treatment option identification, and clinical trial eligibility assessment, available via telemedicine and direct patient access.
• CRO and Research Services Contract research services including CLIA development, clinical trial assay support, companion diagnostics development, methylation and epigenetics testing, and collaborative research opportunities for pharmaceutical, biotechnology, and academic partners.
• Rapid Lung Panel Rapid testing panel for lung cancer diagnostics providing quick turnaround for NSCLC assessment as part of Protean's clinical laboratory test menu.
• Epigenetic Profiling Test Test analyzing epigenetic changes and methylation patterns for cancer characterization and research applications as part of Protean's precision oncology test menu.

Quantifiable outcome

• Aventa FusionPlus detected potentially actionable variants in half of previously characterized tumor specimens with no known actionable driver
• +1 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability8 records

Feature8 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Nanostics Inc.coreTechnology or Integration · 24 September 2024Partnership to launch CDX Prostate (ClarityDX Prostate) in the United States for men at risk of aggressive prostate cancer. The test uses AI-powered learning models to generate risk scores. Protean's CLIA-certified laboratory in Orlando performs the testing. This is a major milestone for Nanostics to expand US market access.
• Pictor, Inc.coreTechnology or Integration · 19 September 2024Collaboration to develop and validate the Pictor PictHealth Extractable Nuclear Antigen (ENA) IgG Multiplex ELISA for autoimmune disease diagnosis. Protean will develop the assay which identifies antibodies associated with lupus and connective tissue disorders. Partnership supports development of other products for rapid and affordable diagnostic solutions.
• Aventa Genomics (Joint Venture with Arima Genomics)coreStrategic or Co-development Partner · 4 October 2023Aventa Genomics is a joint venture between Arima Genomics and Protean BioDiagnostics to commercialize 3D genomics-based tests. The Aventa FusionPlus test is the first clinical application, detecting gene fusions across 361 genes with 100-1000x signal amplification. Joint venture combines Arima's technology expertise with Protean's clinical laboratory capabilities.
• TraveracoreTechnology or Integration · 22 August 2023Protean is Travera's first Center of Excellence for Rapid Therapy Guidance testing. Partnership brings treatment options to advanced carcinoma patients by determining response to specific drugs using live tumor cell screening. Indicated for 39 cancer types and 100+ FDA-approved therapies. Patients receive no-cost access through Protean MAPS platform.
• RochecoreTechnology or Integration · 11 August 2023Collaboration on DelPHI project with Roche to accelerate access to precision oncology for community-based oncology programs. Research published comparing variant annotation software solutions including Roche's navify Mutation Profiler.
• ChromaCodecoreTechnology or Integration · 10 August 2023Strategic partnership to introduce HDPCR-based NSCLC (non-small cell lung cancer) assay in the US through early access program. The assay addresses barriers to advanced diagnostics due to cost, slow turnaround times, and inadequate tissue samples. Florida is targeted as the state accounts for approximately 10% of cancer incidence in the US.
• BioceptminorStrategic or Co-development Partner · 23 February 2021Research collaboration to demonstrate advantages of Biocept's Target Selector assay kit for EGFR mutation determination in non-small cell lung cancer patients. Study focused on tumor sample analysis.
• DiaceuticsminorGTM or Marketing Partner · 14 September 2020CEO Anthony Magliocco joined Diaceutics' Expert Advisory Panel powering its industry-changing diagnostic network DxRx. Diaceutics is building a diagnostic network for precision medicine.
• UCF Business Incubation ProgramcoreStrategic or Co-development Partner · 3 September 2020Protean moved headquarters to Orlando and joined the UCF Business Incubation Program's Lake Nona site. Program supports innovation companies with resources for growth. Company committed to creating jobs in the Orlando area.
• NucleaicoreTechnology or Integration · 11 June 2019Partnership to commercialize advanced AI-based diagnostics for US pathology market with initial focus on improving quality of prostate cancer pathology diagnosis in urology practices. Dr. Magliocco participated as panelist at Precision Medicine Leaders Summit on digital pathology impact.
• University of South Florida (USF)minorStrategic or Co-development Partner · 11 March 2019Original company launch associated with USF campus. Company showcased at USF Connect. Dr. Magliocco served as Clinical Associate Professor at USF College of Medicine.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Personalis: Precision oncology company offering comprehensive genomic profiling (NeXT Personal) with emphasis on ultra-sensitive detection of variants and fusions. Closely comparable technology positioning to Protean's MAPS and Aventa FusionPlus, with similar focus on solid-tumor fusion detection.
• Fulgent Genetics: Clinical diagnostic lab offering NGS-based hereditary cancer testing (particularly with its Beacon carrier and cancer panels) and oncology profiling. Comparable to Protean on whole-exome hereditary risk (Risk MAPS) and precision oncology testing, with broader test menu.
• Caris Life Sciences: Precision oncology company offering comprehensive molecular profiling (MI Profile, MI Cancer Seek), ADAPT tissue-based functional profiling, and AI-driven trial matching. Closely comparable to Protean across multi-omic profiling, functional therapy guidance, and AI trial matching, with broader commercial scale.

Broad incumbents

• Natera: Cell-free DNA testing company with oncology franchise (Signatera tumor-informed MRD) and partnerships in hereditary cancer risk testing. Comparable to Protean on blood-based oncology testing and hereditary risk (Risk MAPS), but at much larger scale across multiple disease areas.
• Veracyte: Genomic diagnostics company with oncology franchise (Decipher Prostate, Afirma thyroid) using whole-transcriptome and methylation-based assays. Comparable to Protean on methylation/epigenetics testing and prostate cancer diagnostics (CDX Prostate competitive set).
• Tempus Labs: AI-enabled precision medicine company offering multi-modal NGS profiling, digital pathology, and clinical trial matching at scale. Competes with Protean's MAPS offering in oncology profiling, AI clinical trial matching, and decision support, though at a substantially larger footprint.
• NeoGenomics: Specialized oncology reference laboratory offering comprehensive genomic profiling, liquid biopsy, and pathology services to community oncologists. Comparable target customer base to Protean and overlapping test menu including NGS and methylation profiling.
• Foundation Medicine: Roche-owned leader in comprehensive genomic profiling (FoundationOne CDx) for solid tumors, with national lab operations and biopharma companion-Dx partnerships. Directly comparable to Protean as a clinical NGS and molecular profiling lab serving oncologists, but at vastly larger scale and with broader payer coverage.
• Exact Sciences: Large diagnostics company offering Cologuard and the Oncotype DX franchise, with growing precision oncology menu including liquid biopsy. Comparable to Protean on hereditary cancer risk and oncology molecular diagnostics, though focused on screening and minimum residual disease.
• Guardant Health: Specialist in liquid biopsy and comprehensive genomic profiling (Guardant360, Guardant Reveal). Comparable to Protean in precision oncology testing with strong focus on blood-based assays, AI, and biopharma partnerships; much larger scale and capital base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/proteanbiodx

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Protean BioDiganostics Inc